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Aim To develop a new method of health-economic analy-
sis based on a marginal approach.
Methods We tested the research hypothesis that a detailed 
comparative a priori incremental cost-effectiveness analy-
sis provides the necessary input for budget impact analy-
sis about the proper order of introduction of new thera-
pies, and thus maximizes the cost-effectiveness bounded 
by the total budget constraint. For the analysis we chose a 
combination therapy for the treatment of hepatitis C virus 
(HCV) genotype 1 (GT1) infection, which was approved by 
the European Medicine Agency in 2015. We used the in-
cremental cost-effective approach to assess the increase 
in the percentage of patients achieving sustained virologi-
cal response (SVR) and the expenditure per additional SVR 
modulated by the new therapy’s market entrance dynam-
ics. Patient subpopulations were differentiated by their re-
sponse to previous treatment, presence of cirrhosis, and 
HCV GT1 subtype. Final parameters were estimated by 
Monte Carlo simulations.
Results The new combination therapy had high efficacy, 
shorter duration, and was better tolerated than alterna-
tive interventions. The research hypothesis was confirmed: 
gradual introduction of the new therapy on the market, 
based on a priori incremental cost-effectiveness analysis, 
would result in average increase in successfully treated pa-
tients by 20%-40%, while additional costs would approxi-
mately be between 8%-40%, ie, €21 000-52 000 per addi-
tional patient achieving SVR.
Conclusion We showed the new combination therapy 
to be cost-effective for certain patient subpopulations, 
especially for experienced cirrhotic HCV GT1 patients. Re-
sults of the analysis are in agreement with the latest rec-
ommendations for HCV patients’ treatment in Croatia. This 
economic evaluation could serve as a starting point for 
negotiations between pharmaceutical industry and insur-
ance companies.
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For European Union (EU) Member States (MSs), being 
part of the common market means that prices of drugs/
therapies cannot be adjusted to individual markets’ op-
tima. Namely, the price is determined by the EU domi-
nant market, formed by Germany, France, United King-
dom, Italy, and Spain (EU5). The EU Treaty specifically 
forbids price discrimination by direct segmentation, ie, 
discrimination according to the country of residence or 
nationality (1). As a consequence, patients from poorer 
EU member states are either paying higher prices or are 
left without adequate health care because of its unaf-
fordability.
Another challenge for those dealing with health-econom-
ic aspects of the introduction of a new medicine on the 
low/middle income EU MSs’ market, is imposed by Health 
Management Organizations (HMOs) that do not use health 
state or utility based allocation mechanisms, such as qual-
ity adjusted life years (QALYs), health adjusted life years 
(HALYs), or disability adjusted life years (DALYs), but base 
their decisions on ordinary budget impact analyses (BIA). 
New, highly effective therapies can be extremely expen-
sive, and if the decision about their inclusion on the reim-
bursement list is based only on ordinary BIA, the impact 
on low/middle income EU MSs’ HMOs’ budgets might be 
unacceptable.
The aim of the article is to develop a new method of 
health-economic analysis based on a marginal approach. 
Using this approach it is possible to show that, despite 
the high price, the new medicine/therapy can still be ac-
ceptable even for less wealthy EU MSs. In order to achieve 
the aim, we tested the research hypothesis that a detailed 
comparative a priori incremental cost-effectiveness analy-
sis provides the necessary input for BIA about the proper 
order of introduction of new therapies, and thus maxi-
mizes the cost-effectiveness bounded by the total budget 
constraint.
Data anD MethoDs
an example of extremely expensive therapy: new 
hepatitis C virus combination therapy
As an example of a new and expensive therapy we chose 
the ombitasvir, paritaprevir, ritonavir, and dasabuvir (OBV/
PTV/r/DSV) combination therapy for hepatitis C virus 
(HCV) infection. OBV/PTV/r/DSV combination therapy is 
an all-oral, interferon-free therapy that suppresses the vi-
ral replication in infected cells, leading to virus elimination 
(2). The therapy combines direct acting antivirals (DAAs) 
with different mechanisms of action and resistance pro-
files that do not overlap, targeting the HCV in its different 
life cycle stages (2).
From pharmacological point of view, OBV/PTV/r/DSV ther-
apy meets the requirements for new therapeutic protocols: 
better efficacy, shorter duration, and better tolerance in 
comparison to currently available therapies (2,3). It is, along 
simeprevir- (SIM) and sofosbuvir- (SOF) based therapies, a 
new HCV therapy that has been approved in Europe dur-
ing the last three years. Due to their sky-high prices, these 
therapies are often referred to as “1000 $ per pill” therapies. 
Their prices breach the budget constraints of many coun-
tries and impose additional allocation requirements on de-
cision-makers (4-7).
table 1. sVR ranges and therapy durations for different hCV Gt1 patient subgroups and treatment regimens*
hCV Gt1 patient obV/PtV/r/DsV pegIFn boC+pegIFn tPV+pegIFn sIM+pegIFn
subgroup no cirrhosis cirrhosis no cirrhosis cirrhosis no cirrhosis cirrhosis no cirrhosis cirrhosis no cirrhosis cirrhosis
sVR (%)
naive 1a: 95.9 1b: 100 1a: 94.6 1b: 100 35-50 33-38 52-67 52-55 64-85 53-71 68-84 57-60
relapsers 1a: 94 1b:100 1a, 1b: 100 13-35  7-25 75-93 34-54 83-88 74.2-84 57-82 46-74
partial responders 1a, 1b: 100 1a: 100 1b: 85.7  0-43  5-20 52-67 34-38 54-79 34-40 57-79 46-82
null responders 1a: 95.4 1b: 100 1a: 92.9 1b: 100  0-8  0-10 38-39  0-34 33-43 14-19 33-66 31-46
therapy duration (weeks)
naive 12 1a: 24 1b: 12 24/48 48 28/48 48 24/48 48 24 24
relapsers 12 1a: 24 1b: 12 48 48 48 48 24/48 48 24 24
partial responders 12 1a: 24 1b: 12 48 48 48 48 24/48 48 48 48
null responders 12 1a: 24 1b: 12 48 48 48 48 48 48 48 48
*sVR – sustained virological response; hCV Gt1 – hepatitis C virus genotype 1; 1a, 1b – hCV Gt1 subtypes; obV/PtV/r/DsV – ombitasvir, paritapre-
vir, ritonavir and dasabuvir (2); pegIFn – pegylated interferon (13,16,17); boC – boceprevir (13,18-23); tPV – telaprevir (13,16,18,24); sIM – simeprevir 
(19,25).
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an example of low/middle income european Union 
Member state: Croatia
Croatia was chosen as an example of low/middle income 
EU MS. Croatian Health Insurance Fund (CHIF), the nation-
al and only social health provider in Croatia, does not use 
health state or utility based allocation mechanisms (8), 
such as QALYs, HALYs, or DALYs. Instead of this, the CHIF’s 
decisions are based on BIA. Croatia is a low HCV prevalence 
country (<2% chronically HCV infected individuals), with 
genotype 1 (GT1) as the most common genotype (approx-
imately 60% of HCV population) (7,9-11). The predominant 
HCV GT1 subtype is 1b (64%), followed by subtype 1a (22%) 
and unknown subtype infection or mixed infection (14%) 
(10). Due to the lack of official epidemiological data, the 
number of experienced patients eligible for new treatment 
(90-100 per year) was estimated according to the opinion 
of Croatian practitioners dealing with HCV patients. It is im-
portant to emphasize that this range is a rough estimate 
and should not be used for other purposes.
health-economic analysis
The analysis was performed from the CHIF’s perspective and 
only the short-term outcomes of the therapy (one year) were 
analyzed. Since OBV/PTV/r/DSV therapy lasts 12-24 weeks 
and has resulted in high sustained virological responses 
(SVR) in clinical trials (2), we considered the short term ther-
apy outcomes to be more relevant for the health-econom-
ic analysis than the life-time horizon. The analysis was per-
formed at the time when OBV/PTV/r/DSV was about to enter 
the Croatian market (year 2015). The therapies present on 
the market at that time were pegylated interferon (pegIFN), 
boceprevir (BOC+pegIFN), telaprevir (TPV+pegIFN), and sim-
eprevir (SIM+pegIFN)-based regimens. These therapies were 
used as alternative therapies to OBV/PTV/r/DSV in the study. 
Therapies’ costs were limited to direct costs and calculated 
according to publicly available CHIF’s medication prices (12) 
and currently valid therapy protocols for HCV GT1 patients 
(13). Therapy prices were expressed in € 2015 (14). Ribavi-
rin (RBV) is donated to the CHIF by pharmaceutical compa-
nies so its price was not used in calculations. For this reason, 
although they include RBV the therapies are designated as 
pegIFN, BOC+pegIFN, TPV+pegIFN, SIM+pegIFN, and OBV/
PTV/r/DSV. In calculations, pegIFN alfa-2a price was used, 
since experience from practice suggests that this pegIFN 
type has been mostly used in Croatia (15).
The used inputs also include duration and SVR rates for 
OBV/PTV/r/DSV therapy and alternative regimens 
(Table 1). These were derived from clinical trials and pub-
lished literature for OBV/PTV/r/DSV (2), pegIFN (13,16,17), 
TPV (13,16,18,24), BOC (13,18-23), and SIM-based regimens 
(19,25). SVR rates were expressed as ranges of values found 
in the cited literature.
Comparisons of health-economic outcomes were made 
across treatment regimens for 4 groups of naive patients 
and 12 groups of experienced HVC GT1 patients. Group-
ing was made according to genotype (GT1a and GT1b, 
where GT1a encompassed mixed type as well), response 
to prior treatment (relapse, partial response, null response), 
and presence of cirrhosis. The analyzed health-economic 
outcomes were: I) cost-effectiveness; II) budget impact; III) 
number of successfully treated patients; IV) expenditures 
per successfully treated patient; and V) incremental cost-
effectiveness ratio (ICER).
The specificity of this study is that the cost-effectiveness of 
the new combination therapy was the basis for other an-
alyzed health-economic outcomes. Estimated savings per 
SVR brought by OBV/PTV/r/DSV determined the scenari-
os and the dynamics of taking over the market shares. We 
simulated that OBV/PTV/r/DSV therapy gradually took over 
the market shares starting with patient subgroups with the 
greatest projected savings per SVR toward subgroups with 
lower projected savings.
For HCV GT1 experienced patients, dual pegIFN+RBV ther-
apy has very low SVR rates: patients with partial and null 
response have SVR rates as low as 0% (Table 1) (16). Due to 
this and the fact that dual therapy has not been included 
in CHIF’s guidelines for treatment of HCV GT1 experienced 
patients (12), the calculation for experienced patients con-
sidering dual therapy was not conducted. BOC, TPV, and 
pegIFN, therapies gain more success in the treatment of 
non-GT1 HCV patients than of GT1 patients (26). Therefore, 
since GT 2, 3, 4, 5, and 6 can be successfully treated with 
therapies that are significantly cheaper than OBV/PTV/r/
DSV, these genotypes were not included in the present 
analysis.
statistical analysis
The results of cost-effectiveness analyses and the num-
ber of patients and SVR rates for specific regimens and pa-
tient groups were varied across complete ranges in 10 000 
Monte Carlo simulation runs. Calculations were performed 
in Microsoft Excel (Microsoft Corp., Redmond, WA, USA). 
Monte Carlo simulation results were analyzed by ANOVA 
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and Tukey post-hoc test. Differences were considered sta-
tistically significant at the level of P < 0.05. Statistical analy-
sis was performed in Statistica 12.0 software (StatSoft Inc, 
Tulsa, OK, USA).
ResUlts
Cost-effectiveness
The results of the cost-effectiveness analysis are presented 
as average therapies’ costs per SVR (Table 2) and as savings 
per SVR of OBV/PTV/r/DSV combination therapy in com-
parison to alternative therapies. Differences between aver-
age OBV/PTV/r/DSV costs per SVR and average costs per 
SVR of alternative regimens were significant (P < 0.001). For 
naive patients the savings are presented in Figure 1, and for 
experienced patients without cirrhosis and with cirrhosis, 
respectively, in Figures 2A and 2B. Positive values were ob-
tained when OBV/PTV/r/DSV therapy was projected to be 
cheaper per SVR than rival therapies (savings), and nega-
tive values were obtained when OBV/PTV/r/DSV therapy 
was projected to be more expensive than rival therapies 
(expenditures). The figures show arithmetic means and 
ranges rather than standard deviations in order to cover 
all possible situations, ie, to show minimum and maximum 
possible savings/expenditures.
In naive patient subgroups, the model projected the stan-
dard dual therapy to be the cheapest one, not only when 
real costs were taken into account but also when costs per 
achieved SVR were compared (Table 2, Figure 1). Only in 
the HCV GT1b (CC) subgroup of naive patients, consider-
able savings per SVR of the OBV/PTV/r/DSV therapy were 
predicted in comparison to rival protease inhibitor (PI) 
regimens (Figure 1). In non-cirrhotic null-responders, the 
introduction of OBV/PTV/r/DSV would result in consider-
able savings per achieved SVR (Table 2, Figure 2A). Also, 
the savings per SVR would be realized for non-cirrhotic 
partial responders who would otherwise be treated with 
BOC or SIM. For other subgroups of experienced non-cir-
rhotic patients, OBV/PTV/r/DSV costs were comparable or 
higher than the costs of rival therapies. In experienced CC 
patients, OBV/PTV/r/DSV therapy was, in most of the cas-
es, the cheapest. The only cheaper options in experienced 
table 2. Direct therapy costs and average therapy costs per sVR (obtained by Monte Carlo simulation) for different hCV Gt1 patient subgroups and treat-
ment regimens*
hCV Gt1 patient obV/PtV/r/DsV pegIFn boC+pegIFn tPV+pegIFn sIM+pegIFn
subgroup no cirrhosis cirrhosis no cirrhosis cirrhosis no cirrhosis cirrhosis no cirrhosis cirrhosis no cirrhosis cirrhosis
therapy costs (Vat included) (€)
naive 45 000 1a: 90 000 1b: 45 000  4200/8400 8400  23 200/32 700 41 900 30 200/34 300 34 300 32 800 32 800
partial responders 45 000 1a: 90 000 1b: 45 000  8400 8400  32 700 41 900 30 200/34 300 34 300 36 900 36 900
null responders 45 000 1a: 90 000 1b: 45 000  8400 8400  41 900 41 900 34 300 34 300 36 900 36 900
average therapy costs per successfully treated patient (€)
naive 1a: 46 900 1b: 45 000 1a: 95 200 1b:45,000 15 000 23 700  47 300 78 300 43 600 52 400 43 200 56 000
relapsers 1a: 47 900 1b: 45 000 1a: 90 000 1b: 45 000 - -  39 200 96 900 37 700 43 500 47 600 55 700
partial responders 45 000 1a: 90 000 1b: 52 500 - -  55 300 116 000 49 200 93 000 54 700 59 300
null responders 1a: 47 200 1b: 45 000 1a: 96 900 1b: 45 000 - - 108 800 -  9  900 207 400 77 400 97 100
*sVR – sustained virological response; hCV Gt1 – hepatitis C virus genotype 1; 1a, 1b – hCV Gt1 subtypes; obV/PtV/r/DsV – ombitasvir, paritaprevir, ritonavir and dasabu-
vir; pegIFn – pegylated interferon; boC – boceprevir; tPV – telaprevir; sIM – simeprevir
FIGURe 1. Results of Monte Carlo simulation: average savings 
per sVR (horizontal lines) and savings’ ranges (vertical lines) 
of obV/PtV/R/DsV therapy compared to rival therapies for 
hCV Gt1 naive patients with and without cirrhosis. Positive 
values: costs of obV/PtV/r/DsV therapy per sVR are expected 
to be lower than costs of rival therapies. negative values: 
costs of obV/PtV/r/DsV therapy per sVR are expected to be 
higher than costs of rival therapies. sVR – sustained virological 
response, hCV Gt1 – hepatitis C virus genotype 1, 1a, 1b – 
hCV Gt1 subtypes, obV/PtV/r/DsV – ombitasvir, paritaprevir, 
ritonavir, and dasabuvir, pegIFn – pegylated interferon, tPV – 
telaprevir + pegIFn, boC – boceprevir + pegIFn, sIM – simepre-
vir + pegIFn; CC - compensated cirrhosis.
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CC population were SIM based therapy for GT1a partial re-
sponders and both SIM and TPV regimens for GT1a relaps-
ers (Table 2, Figure 2B).
budget impact analysis
Since the cost-effectiveness analysis showed that for naive 
patients the standard dual pegIFN therapy was the cheap-
est one compared to alternative regimens regardless of cir-
rhosis status (Figure 1), we assumed it remains the stan-
dard of care (SOC) for naive HCV GT1 population, and this 
group of patients was not included in BIA. The BIA was per-
formed in order to calculate the financial impact of market 
inclusion of OBV/PTV/R/DSV therapy on CHIF’s budget. To 
better capture the incremental effect of the changes, four 
BIA scenarios that systematically increased the OBV/PTV/r/
DSV market shares according to increases in OBV/PTV/r/
DSV costs per achieved SVR (Figure 3) were developed. In 
the first scenario, the OBV/PTV/r/DSV therapy took over 
only the market shares of the competitors that were less 
cost-effective per SVR under simulated circumstances. In 
the second scenario, the OBV/PTV/r/DSV therapy took over 
the market shares of HCV GT1 experienced patients for 
whom OBV/PTV/r/DSV average costs per SVR were lower 
than those of the alternative regimens, but there still exist-
ed a possibility that the costs could be greater as well. The 
third scenario implied that OBV/PTV/r/DSV took over the 
FIGURe 2. Results of Monte Carlo simulation: average savings per sVR (horizontal lines) and savings’ ranges (vertical lines) of obV/
PtV/r/DsV therapy compared to rival therapies for hCV Gt1 (A) experienced non cirrhotic patients; (B) experienced cirrhotic 
patients. Positive values: costs of obV/PtV/r/DsV therapy per sVR are expected to be lower than costs of rival therapies. negative 
values: costs of obV/PtV/r/DsV therapy per sVR are expected to be higher than costs of rival therapies. sVR – sustained virological 
response, hCV Gt1 – hepatitis C virus genotype 1, 1a, 1b – hCV Gt1 subtypes, obV/PtV/r/DsV – ombitasvir, paritaprevir, ritonavir, 
and dasabuvir, pegIFn – pegylated interferon; tPV– telaprevir + pegIFn; boC – boceprevir + pegIFn; sIM– simeprevir + pegIFn; CC - 
compensated cirrhosis.
FIGURe 3. Impact on ChIF’s budget following different 
scenarios of obV/PtV/r/DsV entering the market. scenarios: 
1 – obV/PtV/r/DsV takes over only the market shares of rival 
therapies that have higher costs per sVR; 2 – obV/PtV/r/DsV 
additionally takes over the patient subgroups for which its 
average costs per sVR are more favorable, but the range of 
modeled savings per sVR is such that there is also a chance for 
obV/PtV/r/DsV to be more expensive than the rival therapies; 
3 – additionally to two previous scenarios, obV/PtV/r/DsV 
takes over the market shares of the rival therapies that have 
up to €10 000 lower average costs per sVR; 4 – obV/PtV/r/DsV 
takes over the entire market. ChIF – Croatian health Insurance 
Fund, obV/PtV/r/DsV – ombitasvir, paritaprevir, ritonavir, and 
dasabuvir, sVR – sustained virological response.
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market shares for which it was on average €10 000 more 
expensive in comparison to the rivals. In the final scenario, 
OBV/PTV/r/DSV took over the entire market. According to 
described scenarios, OBV/PTV/r/DSV market entry would 
cost CHIF additional €0.25-1.4 mil per year (Figure 3), which 
represents expenditure increase of 8%, 20%, 37%, and 43% 
for respective scenarios.
Increase in the number of successfully treated patients 
and expenditures per achieved sVR
In order to compare the performance of the OBV/PTV/r/
DSV and alternative regimens, Monte Carlo simulations 
were carried out to calculate the percentage of experi-
enced patients who would achieve SVR depending on 
OBV/PTV/r/DSV market shares. Simulations were per-
formed according to the same scenarios used in BIA. The 
number of successfully treated patients significantly in-
creased with every consecutive scenario (P < 0.001) (Fig-
ure 4). Without OBV/PTV/r/DSV on the market, the aver-
age percentage of patients achieving SVR was 69%, while 
with OBV/PTV/r/DSV on the market this percentage 
ranged from 83% (for the scenario where OBV/PTV/r/DSV 
takes over only the market shares for which it would be 
the cheapest therapy per SVR) up to 98% (for the scenario 
where OBV/PTV/r/DSV takes over the entire market). This 
means that the introduction of OBV/PTV/r/DSV would, 
in analyzed scenarios, on average increase the number 
of successfully treated patients by 20%, 30%, 40%, and 
42%, respectively (Figure 4). Considering expenditures 
per achieved SVR, OBV/PTV/r/DSV was proven to be cost-
effective for the first three scenarios (P < 0.001), while in 
the fourth scenario costs per SVR were slightly higher 
than in the scenario without OBV/PTV/r/DSV (P < 0.001) 
(Figure 5).
Incremental cost-effectiveness ratio
ICER represents additional cost per SVR from an additional 
market share of OBV/PTV/r/DSV taken over from the com-
petition. The average ICER from the lowest OBV/PTV/r/DSV 
market expansion was approximately €21 000, and in the 
scenario when OBV/PTV/r/DSV takes over the entire mar-
ket of HCV GT1 experienced population, the average ICER 
reaches €52 000 (Figure 6).
FIGURe 4. the number of successfully treated patients accord-
ing to the following scenarios: 0 – only rival therapies present 
on the market; 1 – obV/PtV/r/DsV takes over only the market 
shares of rival therapies that have higher costs per sVR; 2 – 
obV/PtV/r/DsV additionally takes over the patient subgroups 
for which its average costs per sVR are more favorable, but the 
range of modeled savings is such that there is also a chance for 
obV/PtV/r/DsV to be more expensive than the rival therapies; 
3 – additionally to two previous scenarios, obV/PtV/r/DsV 
takes over the market shares of the rival therapies that have 
up to €10 000 lower average costs per sVR; 4 – obV/PtV/r/
DsV takes over the entire market. obV/PtV/r/DsV – ombitasvir, 
paritaprevir, ritonavir, and dasabuvir, sVR – sustained virologi-
cal response.
FIGURe 5. expenditure per sVR according to the following sce-
narios: 0 – only rival therapies present on the market; 1 – obV/
PtV/r/DsV takes over only the market shares of rival therapies 
that have higher costs per sVR; 2 – obV/PtV/r/DsV addition-
ally takes over the patient subgroups for which its average 
costs per sVR are more favorable, but the range of the savings 
is such that there is also a chance for obV/PtV/r/DsV to be 
more expensive than the rival therapies; 3 – additionally to 
two previous scenarios, obV/PtV/r/DsV takes over the market 
shares of the rival therapies that have up to €10 000 lower av-
erage costs per sVR; 4 – obV/PtV/r/DsV takes over the entire 
market. obV/PtV/r/DsV – ombitasvir, paritaprevir, ritonavir, 
and dasabuvir, sVR – sustained virological response.
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DIsCUssIon
By using the marginal cost-effectiveness approach to de-
cide on the order of introduction of new therapies as in-
puts into BIA, we showed that, in spite of its high price, the 
new combination therapy could still be acceptable even 
for a less wealthy EU MS. As an example we used OBV/
PTV/r/DSV therapy for HCV GT1 treatment. OBV/PTV/r/DSV 
protocols take half the time the first generation PI thera-
pies take, and clinical trials indicate their high efficacy. 
Since shorter treatments with fewer side-effects increase 
adherence to treatments (27), higher effectiveness of OBV/
PTV/r/DSV compared to the first generation PI therapies 
may also be expected.
In the case of OBV/PTV/r/DSV combination therapy, the 
mentioned approach resulted in four scenarios based on 
discrete market shares provided by each scenario. Accord-
ing to these scenarios, an average rise in expenditure of 
8%, 20%, 37%, and 43%, would result in an average in-
crease of 20%, 30%, 40%, and 42% of successfully treated 
patients, respectively. In the first scenario, the OBV/PTV/r/
DSV therapy takes over the market shares of less cost-ef-
fective competitors, ie, a large portion of patients with cir-
rhosis and all null responders without cirrhosis. So, in the 
cases where cirrhotic patients were the dominant group of 
experienced HCV population, the relation of an expendi-
ture increase and an increase in the number of successfully 
treated patients may be even more favorable.
Therefore, we can say that the introduction of OBV/PTV/r/
DSV combination therapy onto the CHIF reimbursement 
list would have a significant budget impact, but there also 
might be expected a substantial increase in the potential 
number of cured persons. We found the results of the sim-
ulation of the expenditure per SVR especially interesting, 
since they showed the costs per potentially cured person 
to be actually lower for the OBV/PTV/r/DSV combination 
therapy than for rival therapies in all examined scenarios 
but the last one, which is the least possible as it assumes 
complete market takeover by OBV/PTV/r/DSV.
The findings of the analysis are in accordance with the lat-
est Croatian recommendations for the treatment of chronic 
hepatitis C GT1, where OBV/PTV/r/DSV has been recom-
mended for treating all cirrhotic patients and null-respond-
ers (Table 3) (7). In the recommendations, pegIFN remained 
SOC for naive patients with fibrosis stage F1-F2, and the first 
generations PI were replaced by OBV/PTV/r/DSV, SIM-, and 
SOF-based therapies. It is important to mention that SOF 
was not included in the study, since SOF and OBV/PTV/r/
DSV entered the Croatian market simultaneously.
Limitations of our study were a lack of precise epidemio-
logical data, as well as the fact that study included only 
direct therapies’ costs. Presented results were obtained ex-
clusively by quantitative analysis, and their interpretation 
was dominantly economic, while the final decision on the 
medication’s inclusion onto a reimbursement list requires 
table 3. Croatian recommendations for the treatment of hCV 
Gt1 (7)*
hCV Gt1 
patient subgroup Fibrosis score therapy
Naive F1-F2 pegIFN
F3 SIM+pegIFN, SOF+pegIFN
F4/CC OBV/PTV/r/DSV, SOF+SIM
Relapsers and 
partial responders
F1-F3 SIM+pegIFN, SOF+pegIFN
F4/CC OBV/PTV/r/DSV, SOF+SIM
Null responders F1-F4/CC OBV/PTV/r/DSV, SOF+SIM
*hCV Gt1 – hepatitis C virus genotype 1; pegIFn – pegylated interfer-
on; obV/PtV/r/DsV – ombitasvir, paritaprevir, ritonavir and dasabuvir; 
sIM – simeprevir; soF – sofosbuvir; CC - compensated cirrhosis.
FIGURe 6. additional expenditure per additional sVR accord-
ing to the following scenarios: 1 – obV/PtV/r/DsV takes over 
only the market shares of rival therapies that have higher 
costs per sVR; 2 – obV/PtV/r/DsV additionally takes over the 
patient subgroups for which its average costs per sVR are 
more favorable, but the range of the savings is such that there 
is also a chance for obV/PtV/r/DsV to be more expensive than 
the rival therapies; 3 – additionally to two previous scenarios, 
obV/PtV/r/DsV takes over market shares of the rival therapies 
that have up to €10 000 lower average costs per sVR; 4 – obV/
PtV/r/DsV takes over the entire market. obV/PtV/r/DsV – om-
bitasvir, paritaprevir, ritonavir, and dasabuvir, sVR – sustained 
virological response.
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interdisciplinary work, including detailed medical/pharma-
cological considerations.
We showed how highly effective but extremely expensive 
drugs may be acceptable for middle and low income EU 
countries. Nevertheless, as a consequence of EU regula-
tion and the inappropriateness of price discrimination, we 
expect an increase in confidential agreements between 
pharmaceutical industry and health insurance companies, 
with quantity based rebates, and pay-per-cure or other 
similar risk-sharing arrangements. Therefore, there is a ne-
cessity for negotiations between national health insurance 
funds and the pharmaceutical industry, not only concern-
ing this particular case, but also concerning every other ex-
pensive therapy. These negotiations may lead to differen-
tial prices at international level that might seem unfair, but 
are both allocatively efficient and welfare increasing for a 
small and low-income country (28). We propose to allevi-
ate this problem by basing all health-economic outcomes 
of new drugs/therapies on their cost-effectiveness analy-
ses. Cost-effectiveness analysis provides the introduction 
dynamics of a new combination therapy for particular pa-
tient subgroups, which can serve as a basis for budget im-
pact and other connected analyses.
Emergence of new therapies can be both thrilling because 
of remarkable efficacy and puzzling because of extremely 
high prices. The change in the treatment of HCV infection is 
probably one of the most current examples of such a situa-
tion. In order to include the newest therapies on reimburse-
ment lists of middle and low income EU member states, we 
propose to put the cost-effectiveness of new drug thera-
pies on the forefront of the analysis. The new therapy should 
first be introduced to groups of patients for which it has the 
lowest price per successfully treated person, followed by in-
creasingly more expensive scenarios per successful treat-
ment. The analysis was performed from the economic point 
of view, but the final decision on drug inclusion onto the re-
imbursement list requires interdisciplinary work.
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